Hims & Hers Health, Inc. (HIMS)
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Should You Buy Hims & Hers Stock on the Dip?
Hims & Hers (HIMS -4.12%) is taking investors on a roller-coaster ride in 2025.
Hims & Hers Stock Is Down 50% From Its High, but Is This a Buying Opportunity?
Hims & Hers (HIMS -4.12%) stock is down 50% from its peak earlier this year, but the drop in shares hasn't been driven by deteriorating operations. In fact, the company is growing as fast as ever.
3 Cold Stocks That Can Bounce Back This Week
This past week was rough for most investors, but it was a lot harder for a handful of cascading stocks. There were nearly a dozen U.S. exchange-listed companies with market caps north of $1 billion that tumbled by at least 20% last week.
Hims & Hers: AI-Powered Healthcare Disruption
Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase, and achieved $126 million in GAAP net income. The company's subscriber base reached 2.2 million, growing 45% year-over-year, with 55% of subscribers using at least one personalized treatment. Hims & Hers' GLP-1 weight loss treatments contributed $225 million in incremental revenue, but regulatory and supply risks remain significant concerns.
Hims & Hers to shut down dermatology business Apostrophe
Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on Friday.
Hims and Hers just shut down its dermatology business after stock slump on FDA's weight-loss drug decision
Hims and Hers is shutting down the dermatology business it acquired in 2021, BI has learned. The company said it's closing skincare site Apostrophe to centralize its teledermatology offerings.
Hims & Hers: The Odds Are In Your Favor, Here's How To Take Advantage (Rating Upgrade)
Hims & Hers Health is now reasonably valued after its large drop, making it a cautious Buy due to its high growth potential. The company's revenue grew 69% YoY to $1.5 billion, driven by a 45% increase in subscribers and higher average revenue per subscriber. To mitigate risk, consider selling call options against HIMS shares, leveraging high implied volatility for a favorable risk-reward proposition.
This Could Be a Huge Blow to Hims & Hers Health Stock
Hims & Hers Health (HIMS -15.90%) has been a top healthcare stock to own over the past five years, soaring by around 350% during that stretch. By focusing on offering customers personalized telehealth options, the business has experienced tremendous growth.
Why Hims & Hers Stock Just Collapsed
Hims & Hers Health (HIMS -12.33%) stock took a tumble Thursday morning, falling 9.2% through 11:40 a.m. ET on some (vicariously) bad news out of the Great State of Texas.
Healthcare Stock Could Be Good 'Buy the Dip' Play
The shares of healthcare name Hims & Hers Health Inc (NYSE:HIMS) have retreated from their Feb. 19, pre-earnings all-time high of $72.98.
Novo Nordisk's Cheaper Wegovy Offering Is Bad News for Hims & Hers
The announcement comes weeks after the FDA declared that Wegovy is no longer in shortage.
